Clinical Trials Logo

Clinical Trial Summary

The Anaphylaxis Registry aims to assess data in a standardized form about symptoms, triggers, cofactors and therapy management from patients who experienced an anaphylactic reaction. This should improve diagnosis and long-term management of these life-threatening allergic reactions.


Clinical Trial Description

A better understanding of the triggers and pathology of anaphylactic reactions could lead to a better diagnosis and prophylaxis to avoid the occurence of these life-threatening allergic reactions. This can be an advantage for affected persons regarding the their treatment and long-term management. The Anaphylaxis Registry is an opportunity to gather these standardized data. The blood sampling is optional for the patient, however, it will contribute to the better understanding of the sensitization profile and possible mechanisms. Recent publications showed a correlation between an anaphylactic reaction and certain biomarkers. Those data will be validated in a larger number of population with identification of further biomarkers. It is presumed that certain genetic and epigenetic polymorphisms are abundant for patients who experienced an anaphylaxis. To summarize, this study aims to contribute to a better understanding of the anaphylaxis in general, the diagnosis, and the prognosis with different severities. With the identification of a certain trigger, the obtained understanding may help to decrease the risk of or prevent future repeating reactions. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05210543
Study type Observational [Patient Registry]
Source Charite University, Berlin, Germany
Contact Margitta Worm, Prof.
Phone +49 30 450 518105
Email [email protected]
Status Recruiting
Phase
Start date January 1, 2007
Completion date December 2030

See also
  Status Clinical Trial Phase
Not yet recruiting NCT04475003 - Health Literacy Among Caregivers of Children With IgE-mediated Allergy With Risk of Anaphylaxis
Recruiting NCT04615065 - Acutelines: a Large Data-/Biobank of Acute and Emergency Medicine
Completed NCT00047918 - Blood Factors in Mastocytosis and Unexplained Anaphylaxis and Flushing N/A
Active, not recruiting NCT03953482 - Evaluation of Medical Care and Patient's Knowledge About the Behavior to Take on Secondary Prevention of Anaphylaxis
Recruiting NCT05112367 - Epidemiology and Management of Pediatric Anaphylaxis and Allergy in the Pediatric Emergency Department of Montpellier
Completed NCT03366298 - Pharmacokinetics of Intramuscular Adrenaline in Food--Allergic Teenagers Phase 4
Completed NCT02958605 - Smartphone Apps for Pediatric Resuscitation N/A
Completed NCT04696822 - Bioavailability of Nasal Epinephrine Phase 1
Completed NCT03942692 - What is the Allergy Follow-up for Children After Anaphylactic Reaction? AFCAR : Allergy Follow-up for Children After Anaphylactic Reaction
Completed NCT02854969 - Satisfaction of Patient With Anaphylaxis in the Use of a Medical Device N/A
Completed NCT03282929 - Study to Explore the Pharmacokinetics and Pharmacodynamics of Epinephrine in Healthy Male and Female Subjects With Different Skin to Muscle Depth (STMD) Phase 1
Recruiting NCT01326741 - Clonal Mast Cell Disorders in Exercise-Induced Anaphylaxis N/A
Completed NCT01217138 - Make up for the Epinephrine Autoinjector Phase 4
Completed NCT02424136 - PEAnut Anaphylaxis Predictors N/A
Completed NCT01432522 - A Study for Absorption of Intranasal Epinephrine Compared to Conventional Intramuscular Epinephrine N/A
Completed NCT02028065 - A Study to Evaluate the Incidence of Hypersensitivity After Administration of Sugammadex in Healthy Participants (MK-8616-101) Phase 1
Active, not recruiting NCT01247415 - Clinical Investigation on Allergic-like Reactions and Oculo-respiratory Syndrome After the H1N1 Pandemic Vaccine N/A
Completed NCT00868842 - Desensitization of Human Mast Cells: Mechanisms and Potential Utility for Preventing Anaphylaxis N/A
Completed NCT04290507 - Epidemiology and Outcome of Anaphylactic Shocks Admitted to Intensive Care Unit
Completed NCT01361347 - Safety of Oral Immunotherapy for Cow's Milk Allergy in School-aged Children Phase 4